Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Golden Meditech Collaborates to Develop Stem Cells for Neurodegeneration

publication date: Apr 19, 2019

Golden Meditech, a China medical device and healthcare management company, will collaborate with the Department of Biology of Hong Kong Baptist University to research the use of stem cells to treat neurodegenerative diseases. The company said HKBU is already researching stem cell therapy as a neurodegenerative treatment, with some results commercialized. Golden Meditech recently closed the sale of its 65% stake in China Cord Blood, a stem cell/cord blood storage company, for $860 million. More details....

Stock Symbol: (HK:00801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.